Therapeutic drug monitoring in CML patients on imatinib.

نویسندگان

  • Carolyn Blasdel
  • Merrill J Egorin
  • Theodore F Lagattuta
  • Brian J Druker
  • Michael W Deininger
چکیده

each, although toxicities were not directly attributed to the agent.2 In their letter, Chamberlain and Glantz comment on the neurologic syndromes we reported and question attribution to liposomal cytarabine. Our attributions were based on 15-year experience in nearly 500 adults with acute lymphoblastic leukemia without central nervous system (CNS) disease, treated with hyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) and standard CNS prophylaxis (methotrexate 12 mg day 2; cytarabine 100 mg day 7 for 3-8 cycles). In this setting, seizures are extremely uncommon (3 of 482 patients [0.006%]). The long half-life of liposomal cytarabine made attribution plausible in patient 1, given absence of discernable metabolic or other etiology. We have not observed hydrocephalus with standard CNS prophylaxis. Obesity and corticosteroids contribute to pseudotumor cerebri. Patient 2 was not obese, and dexamethasone dosing was only slightly increased. Investigators in our Department of NeuroOncology have also attributed anecdotal hydrocephalus cases to liposomal cytarabine (Morris D. Groves, M. D. Anderson Cancer Center, written personal communication, March 22, 2007). These data, taken in aggregate with the case in the lymphoma trial, raise the question whether association of hydrocephalus with liposomal cytarabine has been unrecognized or underreported. Findings for patient 3 are better described as partial cauda equina syndrome or sacral radiculopathy. Although Chamberlain and Glantz suggest any chemotherapy given via lumbar puncture (LP) could cause such neurologic sequelae, we have not observed this after standard CNS prophylaxis given almost exclusively via LP. Decreased perineal sensation and lower-extremity paresthesias in patient 4 were also consistent with sacral radiculopathy. Standard intrathecal chemotherapy was delayed until 4 months later. The morbidity of urinary and/or fecal incontinence associated with these syndromes in 2 of 31 patients was considered unacceptable. Encephalopathy is more appropriate terminology for patient 5; encephalitis implies an inflammatory process. Encephalopathy related to high-dose systemic methotrexate-cytarabine usually manifests during administration or immediately thereafter, not on day 15, in this case approximately 36 hours after liposomal cytarabine. An exhaustive evaluation was unable to discern any other etiology for the neurotoxicity, which led to the patient’s demise. To what degree each agent contributed is an unanswerable question but does not preclude an association. The character, constellation, and severity of neurotoxicity was concerning in potentially curable patients. We felt it prudent to alert other investigators of the need for monitoring and reporting of neurotoxicity if this agent was used in a similar manner. The absence of similar neurotoxicity in the 56 patients treated with standard CNS prophylaxis since terminating the liposomal cytarabine trial further supports our conclusions.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase.

Imatinib is approved as a first-line treatment for Philadelphia chromosome-positive chronic myeloid leukemia (CML). Because of the variability in imatinib exposure among patients, therapeutic drug monitoring to maintain a plasma threshold level of about 1,000 ng/ml would be beneficial during imatinib therapy. Imatinib pharmacokinetics are influenced by body weight, comedication and pharmacogene...

متن کامل

In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.

BACKGROUND Cytochrome P450 3A (CYP3A) isoenzyme metabolic activity varies between individuals and is therefore a possible candidate of influence on the therapeutic outcome of the tyrosine kinase inhibitor imatinib in patients with chronic myeloid leukemia (CML). The aim of this study was to investigate the influence of CYP3A metabolic activity on the plasma concentration and outcome of imatinib...

متن کامل

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients in the Chronic Phase

Imatinib is approved as a first-line treatment for Philadelphia chromosome-positive chronic myeloid leukemia (CML). Because of the variability in imatinib exposure among patients, therapeutic drug monitoring to maintain a plasma threshold level of about 1,000 ng/ml would be beneficial during imatinib therapy. Imatinib pharmacokinetics are influenced by body weight, comedication and pharmacogene...

متن کامل

Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.

Imatinib, nilotinib, and dasatinib are tyrosine kinase inhibitors (TKIs) that have become first-line treatments for Philadelphia chromosome-positive chronic myeloid leukemia (CML). According to European LeukemiaNet recommendations, the clinical response of CML patients receiving TKI therapy should be evaluated after 3, 6, and 12 months. For patients not achieving a satisfactory response within ...

متن کامل

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

Imatinib mesylate (Glivec®; Novartis, Basel, Switzerland), a protein kinase inhibitor of the BCR–ABL fusion protein, has demonstrated significant clinical efficacy in the treatment of Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML). Imatinib mesylate (hereinafter shortly referred to as imatinib) produces durable responses and prolonged survival; therefore, it has become the...

متن کامل

Targeted treatment of chronic myeloid leukemia: role of imatinib

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of pleuripotent hematopoetic stem cells. The incidence of CML is 1 to 2 cases per 100,000 people per year; in the Western Hemisphere, CML accounts for 15% of leukemias in adults. Discovery of the specific karyotypic abnormality of the Philadelphia (Ph) chromosome in the pathogenesis of CML has led ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Blood

دوره 110 5  شماره 

صفحات  -

تاریخ انتشار 2007